Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
bioAffinity Technologies (Nasdaq:BIAF) closed a previously announced public offering for $3.2 million in aggregate gross proceeds, before fees and expenses.
The offering comprised 4,000,000 common shares at $0.80 per share, or pre-funded warrants at $0.793, each exercisable for one common share. WallachBeth Capital acted as sole placement agent.
bioAffinity Technologies (Nasdaq:BIAF) announced the closing of a previously announced public offering for aggregate gross proceeds of $3.2 million, before fees and expenses.
The offering comprised 4,000,000 shares of common stock (or pre-funded warrants) at $0.80 per share or $0.793 per pre-funded warrant, with WallachBeth Capital as sole placement agent.
bioAffinity Technologies (Nasdaq:BIAF) priced a registered public offering for expected gross proceeds of $3.2 million before fees and expenses.
The deal comprises 4,000,000 shares of common stock (or pre-funded warrants) at $0.80 per share, with closing anticipated around June 18, 2026. WallachBeth Capital is sole placement agent.
bioAffinity Technologies (Nasdaq: BIAF) priced a public offering for approximately $3.2 million in gross proceeds. The deal includes 4,000,000 common shares, or pre-funded warrants in lieu, at $0.80 per share or $0.793 per pre-funded warrant.
The offering is made under effective Form S-1 (File No. 333-296764) and is expected to close on or about June 18, 2026, subject to customary conditions. WallachBeth Capital serves as sole placement agent.
bioAffinity Technologies (Nasdaq:BIAF) announced a July 21, 2026 webinar focused on advancing veteran lung health. Clinical experts from Philips, bioAffinity Technologies and 4DMedical will discuss mobile CT screening, noninvasive CyPath® Lung testing, and functional lung imaging for earlier detection and improved management of respiratory disease in U.S. veterans.
bioAffinity Technologies (Nasdaq:BIAF) announced that the Society for Advanced Bronchoscopy will host a webinar on the noninvasive CyPath® Lung test and its role in managing early-stage lung cancer.
The June 16, 7 p.m. ET session will feature a multidisciplinary physician panel sharing real-world clinical use cases.
bioAffinity Technologies (Nasdaq:BIAF) announced notification of allowance from the Mexican Institute of Industrial Property for a patent covering CyPath® Lung methods that predict lung cancer likelihood using flow cytometry.
The patent will protect use of specific antibodies, TCPP porphyrin labeling, and flow cytometry on sputum samples, expanding CyPath® Lung’s intellectual property portfolio that already includes patents in the United States, European Union, China, Japan, Australia, Canada and Mexico.
CyPath® Lung is a commercially available, noninvasive test that combines advanced cell biology, flow cytometry, artificial intelligence and at-home sample collection to help clinicians assess indeterminate pulmonary nodules in high-risk patients, support treatment decisions and potentially reduce healthcare costs.
bioAffinity Technologies (Nasdaq:BIAF) reported record monthly unit sales for its CyPath® Lung diagnostic test in April 2026, with units up nearly 300% versus April 2025 based on preliminary unaudited data.
The company highlights accelerating physician adoption, integration into clinical workflows, and new studies and R&D to expand applications.
bioAffinity Technologies (Nasdaq: BIAF) reported Q1 2026 results and growing adoption of CyPath® Lung. Unit sales rose 146% YoY; CyPath testing revenue was $361,000 (≈114% increase). Total revenue was $1.4M (down ~27%). Q1 net loss was $3.6M or $(0.81) per share. Cash and cash equivalents were $3.1M as of March 31, 2026. The company launched a large longitudinal trial (up to 20 sites) partially funded by the U.S. Department of Defense and reported a 40-patient collaborative study at Brooke Army Medical Center.
bioAffinity Technologies (Nasdaq: BIAF) launched a pilot study with Brooke Army Medical Center to evaluate its flow cytometry+AI tests for identifying inflammatory biomarkers in asthma and COPD. The study will enroll ~40 participants across asthma, COPD and healthy-control cohorts to assess sputum immune cells and cytokines.
The collaboration aims to support precision diagnostics and treatment monitoring for airway diseases and references a potential asthma/COPD treatment market estimated at $92 billion.